Samsung Biologics Faces Earnings Burden Due to Soaring Labor Costs and Strikes... Target Price Lowered by 15%
Samsung Securities lowered Samsung Biologics' target price from 2.1 million won to 1.8 million won on the 21st. While maintaining a 'buy' rating, the firm judged that recent soaring labor costs and production disruptions due to strikes are likely to put a significant burden on this year's earnings.
Catch the next bear flag
Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 52.2%.
Get high-impact news instantly
Top stories with score 8/10+ delivered to your Telegram in real time. Free.
Join Telegram channel